New Drug Offer Hope To Patients With Late Stage Prostate Cancer | Cancer
At present, metastatic and hormonal-refractory prostate cancer patients who have failed 1st line chemotherapy will be given mitoxantrone plus prednisone as the salvage therapy. However, mitoxantrone plus prednisone is not very effective in controlling metastatic prostate cancer. Now, a new drug developed by sanofi-aventis might offer hope to patients who have failed 1st line chemotherapy (docetaxel plus prednisone).
The new drug called cabazitaxel was investigated in the TROPIC tr
new drug offer hope to patients with late stage prostate cancer cancer
After one year of treatment, men in the cabazitaxel arm had an overall median survival of 15.1 months, compared to 12.7 months among men in the mitoxantrone arm. Patients who received the combination treatment with cabazitaxel also experienced a s
Terms
predni, patient, month, meta, aventi, cell, shttpen, detail, sician, athealthrea, article, wwwclinicaltrial, pdfplea, scombinarie, infection, increa
ignificant increase in median progression-free survival, 2.8 months vs. 1.4 months. Note that cabazitaxel was also associated with a 30 percent reduced risk of dying.
Like other chemotherapies, cabazitaxel was associated with side-effects such as low white blood cells (81.7%), low white blood cells with fever (7.5%), diarrhea (6.2%) and infections (10.2%).
This drug has not been approved by FDA, but is under the fast track approval process - process designed to expedite the review of drugs
Category › Cancer
Title › New Drug Offer Hope To Patients With Late Stage Prostate Cancer | Cancer
being developed for serious diseases with the potential to address an unmet medical need. To participate in clinical trials, you may visit www.clinicaltrials.gov for details and contact your physicians.
http://en.sanofi-aventis.com/binaries/20100304_Asco_GU_en_tcm28-27547.pdf
Please visit us at healthreason.com for more articles like this.